Altamira Therapeutics Ltd. has officially requested the United States Securities and Exchange Commission (SEC) to declare its Registration Statement on Form F-1 effective by 4:00 p.m. Eastern Time on April 17, 2024. The request, made in accordance with Rule 461 under the Securities Act of 1933, was submitted through a correspondence filed via EDGAR. The company's CEO, Thomas Meyer, signed the request, which was facilitated by Alex Dinur of Lowenstein Sandler LLP. Altamira Therapeutics is awaiting confirmation from the SEC for the effectiveness of their Registration Statement, which is a critical step in the process of a public offering.

Altamira Therapeutics Ltd. has officially requested the United States Securities and Exchange Commission (SEC) to declare its Registration Statement on Form F-1 effective by 4:00 p.m. Eastern Time on April 17, 2024. The request, made in accordance with Rule 461 under the Securities Act of 1933, was submitted through a correspondence filed via EDGAR. The company's CEO, Thomas Meyer, signed the request, which was facilitated by Alex Dinur of Lowenstein Sandler LLP. Altamira Therapeutics is awaiting confirmation from the SEC for the effectiveness of their Registration Statement, which is a critical step in the process of a public offering.